7 documents found, page 1 of 1
Novel Metal Radiopharmaceuticals for Theranostics in Oncology and Neuroscience
Hrynchak, IvannaTese de Doutoramento em Ciências Farmacêuticas apresentada à Faculdade de Farmácia; O trabalho apresentado nesta tese tem como foco principal a síntese, caracterização e avaliação de uma série de radiofármacos baseados em radiometais, com vista ao desenvolvimento de ferramentas valiosas para translação clínica, particularmente nas áreas de oncologia e neurociência. A pesquisa visa fornecer informações e aplicaç...
Antibody and Nanobody Radiolabeling with Copper-64: Solid vs. Liquid Target App...
Hrynchak, Ivanna; Cocioabă, Diana; Fonseca, Alexandra I.; Leonte, Radu; Carmo, Sérgio do; Cornoiu, Roxana; Falcão, Amílcar; Niculae, DanaAntibody and nanobody-based copper-64 radiopharmaceuticals are increasingly being proposed as theranostic tools in multiple human diseases. While the production of copper-64 using solid targets has been established for many years, its use is limited due to the complexity of solid target systems, which are available in only a few cyclotrons worldwide. In contrast, liquid targets, available in virtually in all cy...
Fully Automated Production of [68Ga]GaFAPI-46 with Gallium-68 from Cyclotron Us...
Fonseca, Alexandra I.; Alves, Vítor H.; Hrynchak, Ivanna; Alves, Francisco68Ga-based radiopharmaceuticals are routinely used for PET imaging of multiple types of tumors. Gallium-68 is commonly obtained from 68Ge/68Ga generators, which are limited in the quantity of activity produced. Alternatively, gallium-68 can easily be produced on a cyclotron using liquid targets. In this study, we optimized the GMP production of [68Ga]GaFAPI-46 using gallium-68 produced via a standard medical cy...
Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibod...
Dewulf, Jonatan; Hrynchak, Ivanna; Geudens, Sarah; Pintelon, Isabel; Vangestel, Christel; Sereno, José; van Dam, Peter A; Abrunhosa, AnteroRANKL expression in the tumor microenvironment has been identified as a biomarker of immune suppression, negating the effect of some cancer immunotherapies. Previously we had developed a radiotracer based on the FDA-approved RANKL-specific antibody denosumab, [89Zr]Zr-DFO-denosumab, enabling successful immuno-PET imaging. Radiolabeled denosumab, however, showed long blood circulation and delayed tumor uptake, p...
Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabelin...
Hrynchak, Ivanna; Santos, Liliana; Falcão, Amílcar; Gomes, Célia M.; Abrunhosa, Antero J.The overexpression of human epidermal growth factor 2 (HER2) in breast cancer (BC) has been associated with a more aggressive tumor subtype, poorer prognosis and shorter overall survival. In this context, the development of HER2-targeted radiotracers is crucial to provide a non-invasive assessment of HER2 expression to select patients for HER2-targeted therapies, monitor response and identify those who become r...
Advances in the automated synthesis of 6-[18F]Fluoro-L-DOPA
Neves, Ângela C. B.; Hrynchak, Ivanna; Fonseca, Inês; Alves, Vítor H. P.; Pereira, Mariette M.; Falcão, Amílcar; Abrunhosa, Antero J.The neurotracer 6-[18F] FDOPA has been, for many years, a powerful tool in PET imaging of neuropsychiatric diseases, movement disorders and brain malignancies. More recently, it also demonstrated good results in the diagnosis of other malignancies such as neuroendocrine tumours, pheochromocytoma or pancreatic adenocarcinoma.The multiple clinical applications of this tracer fostered a very strong interest in the...
Correction to: Advances in the automated synthesis of 6-[18F]Fluoro-L-DOPA
Neves, Ângela C. B.; Hrynchak, Ivanna; Fonseca, Inês; Alves, Vítor H. P.; Pereira, Mariette M.; Falcão, Amílcar; Abrunhosa, Antero J.